The contract research organisation (CRO) has been operating in the Tampa market since 1997 but split from its parent company MDS last May and formed a new firm with the technology to get active pharmaceutical ingredients (APIs) directly into capsules.
The company claims it is the only CRO in North America with this capability.
According to Xcelience, its technology, called Xcelodose, can bypass much formulation work since it removes the need for excipients that are normally required for filling purposes and associated stability studies, helping to shorten the drug development process.
"The laboratory is looking into the future, and preparing to expand where our customers are asking us to," said Derek Hennecke, Xcelience president and CEO.
"That means we'll be growing the analytical, preformulation, formulation, manufacturing and stability services we provide to our wide range of international clients."
By focusing solely on the preformulation, formulation, analytical and manufacturing fields, Xcelience now believes it has the edge in what is widely seen as a saturated market.
Looking forward, the firm said it also planned to boost its employment by about 50 per cent over the next three years.
However, Hennecke added that the firm would not be changing its core scientific procedures.